AmplifyBio: The company raised $100 million of venture funding from undisclosed investors on June 27, 2022. The company is an operator of a biotechnology platform intended to advance the quality of human health and save lives.
MiroBio: The company raised $97 million of Series B venture funding in a deal led by Medicxi on June 29, 2022. OrbiMed, Samsara BioCapital, Advent Life Sciences, SR One, Monograph Capital, and Oxford Science Enterprises also participated in the round. The company is a developer of novel therapeutics technology designed to bring significant benefits to patients suffering from a range of auto-immune diseases.
Tomorrow Health: The company raised $60 million of Series B venture funding in a deal led by Bond Capital (San Francisco) on June 29, 2022, putting the company’s pre-money valuation at $340 million. Andreessen Horowitz, BoxGroup, Obvious Ventures, and Sound Ventures also participated in the round. The company is a developer of a data-driven medical equipment sourcing platform intended to streamline ordering and access to home medical equipment supplies for patients and their families.
Cognito Therapeutics: The company raised $53.33 million of venture funding from FoundersX Ventures and other undisclosed investors on June 28, 2022. The company is a developer of a pipeline of disease-modifying digital therapeutics intended to cure neurodegenerative disorders.
Lumen Bioscience: The company closed on $50.46 million of an undisclosed targeted amount of venture funding on June 29, 2022. The company is a developer of drug development and manufacturing platform designed to transform the way therapeutic drugs are developed.
Faeth: The company raised $47 million of Series A venture funding in a deal led by S2G Ventures on June 29, 2022. KdT Ventures, Khosla Ventures, Future Ventures, Cantos Ventures, Digitalis Ventures and AgFunder also participated in the round. The company is an operator of a data-driven, evidence-based healthcare company intended to use a deep mechanistic understanding of cancer metabolism to help in the treatment of cancer.
Cerebral Therapeutics: The company raised $40 million of Series C venture funding in a deal led by Lynx1 Capital Management on June 28, 2022. Vivo Capital, RA Capital Management, Perceptive Advisors, and Granite Point Capital also participated in the round. The company is a developer of combination therapies intended to improve the lives of patients suffering from chronic neurological diseases.
Matter Health: The company raised $35 million of Series A venture funding in a deal led by Jordan Park on June 29, 2022. The company is a provider of healthcare services intended to bring high-quality preventative and primary care closer to patients’ homes, where they need it most.
Centerline Biomedical: The company raised $33 million of Series B venture funding in a deal led by Cleveland Clinic Ventures on June 27, 2022, putting the company’s pre-money valuation at $67 million. G2 Group Ventures, GE Healthcare, Gana Yantrika Enterprises, Jumpstart Ventures, JobsOhio, and other undisclosed investors also participated in the round. The company is a developer of three-dimensional (3D) visualization and real-time navigation system designed to improve endovascular procedure outcomes and reduce radiation exposure.
Centrexion Therapeutics: The company raised $23.75 million of venture funding in the form of convertible debt from undisclosed investors on June 27, 2022. The company is an operator of a clinical-stage biopharmaceutical company intended to address the unmet medical need for the treatment of chronic pain.
GI Windows: The company raised $14.49 million of venture funding from Johnson & Johnson Innovation on June 29, 2022. The company is a developer of surgical device designed using anastomoses technology to help in tissue fusion.
Ermium Therapeutics: The company raised EUR 12.3 million of Series A venture funding through a combination of debt and equity from Domain Therapeutics, Eurazeo and Idinvest Partners on June 30, 2022, putting the company’s pre-money valuation at EUR 2.38 million. The company is a developer of a biotechnology platform designed for the treatment of autoimmune inflammatory diseases.
Sensible Care: The company received $13 million of development capital from Volition Capital and Skyline Investors on June 30, 2022. The company is a provider of end-to-end online behavioral health services based in Santa Ana, California.
Rational Vaccines: The company raised $11.736 million of venture funding in the form of convertible debt from Flight Ventures, Arab Angel and other undisclosed investors on June 28, 2022. The company is an operator of a biotechnology company intended to combat all diseases resulting from herpes.
Advanced NanoTherapies: The company raised $7.2 million through a combination of Series A-1, Series A-2 and Series A-3 venture funding from undisclosed investors on June 28, 2022, putting the company’s pre-money valuation at $25 million. The company is a developer of biodegradable functionalized nanoparticle technology designed for cardiovascular and endovascular applications.
Deep Blue Medical Advances: The company raised $7.03 million of venture funding from undisclosed investors on June 29, 2022. The company is a developer of a hernia mesh designed to solve the problem of hernia occurrence and recurrence.
LifeLink Systems: The company raised $5.73 million of venture funding from undisclosed investors on June 29, 2022. The company is a developer of a healthcare technology platform designed for deploying, managing, and optimizing chatbots across the full patient care continuum.
Aqualung Therapeutics: The company raised $5.6 million of venture funding in the form of convertible debt from JSR Life Sciences and other undisclosed investors on June 27, 2022. The company is a developer of an early-stage biotech company intended to provide an immune-focused biologic platform for serious inflammatory disorders.
Sonio.AI: The company raised EUR 5 million of venture funding in a deal led by Elaia Partners on June 29, 2022. OneRagtime and Bpifrance also participated in the round. The company is a developer of an artificial intelligence-based fetal ultrasound software intended to help practitioners analyze and diagnose congenital malformations.
Heads Up: The company raised $5.17 million of venture funding from undisclosed investors on June 30, 2022. The company is an operator of a seed-stage technology company intended to provide a new approach to personal health by integrating clinical, lifestyle, nutritional and self-collected data with personalized analytics and insights.
Mindera Health: The company raised $3.5 million of venture funding in the form of convertible notes from undisclosed investors on June 29, 2022. The company is a developer of molecular testing technology designed to be used for skin diseases and conditions.
General Fluidics: The company is in the process of raising venture funding in the form of convertible debt on June 29, 2022 The company is a developer of a Vitro diagnostic tool intended for end-to-end, fully integrated modular IVD for performing a growing array of blood and urine tests.
MMS Holdings: The company received an undisclosed amount of development capital from Lindsay Goldberg on June 28, 2022. The company is an operator of a clinical research organization intended to serve pharmaceutical, biotechnology and medical device industries in the form of research services.
NeuraLace Medical: The company is in the process of raising Series B venture funding on June 29, 2022. The company is a developer of a non-opioid pain reduction system designed to relieve chronic nerve pain.
Pillcheck: The company is in the process of raising venture funding on June 27, 2022. The company is a developer of a proprietary software and service platform designed to unlock the power of DNA to improve health and reduce utilization of healthcare resources.
